IMR Press / CEOG / Volume 40 / Issue 2 / pii/1630388188118-999673838

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research
Maternal adiponectin and visfatin concentrations in normal and complicated pregnancies
Show Less
1 Department of Obstetrics and Gynecology
2 Department of Biostatistics, Faculty of Medicine, Uludag University, Nilufer, Bursa (Turkey)
Clin. Exp. Obstet. Gynecol. 2013, 40(2), 261–267;
Published: 10 June 2013
Abstract

Objective: To evaluate the role of adiponectin and visfatin in the pathophysiology of pre-eclampsia (PE) and how their concentrations correlate with the severity of the disease and neonatal outcomes. Study Design: A prospective case-control study was carried out in 52 preeclamptic and 28 healthy pregnant women during the third trimester. The maternal plasma concentrations of adiponectin and visfatin were determined. Neonatal outcomes were also recorded. Results: Mean maternal plasma adiponectin concentrations in healthy pregnant women did not differ significantly from those of mild PE and severe PE groups. The plasma adiponectin levels of PE patients with small for gestational age (SGA) and those without SGA did not differ significantly, but the median plasma visfatin concentration of patients with SGA fetus was significantly higher if the patient was preeclamptic (p = 0.036). Conclusion: The severity of preeclampsia did not change the plasma levels of adiponectin and visfatin, but the median plasma visfatin concentration of patients with SGA fetuses were significantly higher if the patient was preeclamptic. Altered levels of adipocytokines strongly imply that the regulation of adipocytokines in PE is different and more complex compared to that in healthy pregnancy.
Keywords
Pregnancy
Preeclampsia
Adiponectin
Visfatin
SGA fetuses
Share
Back to top